A citation-based method for searching scientific literature

Eirini Pectasides, Matthew D Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite, Manish R Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca J Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung-Hoon Min, Katie S Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T Agoston, David J Oh, Andrew Dunford, Aaron R Thorner, Matthew D Ducar, Bruce M Wollison, Haley A Coleman, Yuan Ji, Mitchell C Posner, Kevin Roggin, Kiran Turaga, Paul Chang, Kyle Hogarth, Uzma Siddiqui, Andres Gelrud, Gavin Ha, Samuel S Freeman, Justin Rhoades, Sarah Reed, Greg Gydush, Denisse Rotem, Jon Davison, Yu Imamura, Viktor Adalsteinsson, Jeeyun Lee, Adam J Bass, Daniel V Catenacci. Cancer Discov 2018
Times Cited: 176







List of co-cited articles
771 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
43



Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Steven B Maron, Leah M Chase, Samantha Lomnicki, Sara Kochanny, Kelly L Moore, Smita S Joshi, Stacie Landron, Julie Johnson, Lesli A Kiedrowski, Rebecca J Nagy,[...]. Clin Cancer Res 2019
77
31

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, Kyoung-Mee Kim, Jason C Ting, Swee Seong Wong, Jiangang Liu, Yong Gang Yue, Jian Wang, Kun Yu,[...]. Nat Med 2015
23

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Seung Tae Kim, Razvan Cristescu, Adam J Bass, Kyoung-Mee Kim, Justin I Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mijin Lee,[...]. Nat Med 2018
603
22

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier,[...]. Cancer Discov 2018
176
22

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
269
22

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
20

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Florian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, Pamela Salman, Sang Cheul Oh, György Bodoky, Galina Kurteva, Constantin Volovat, Vladimir M Moiseyenko, Vera Gorbunova,[...]. Lancet Oncol 2013
589
20

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
195
19


Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
635
18

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Tom Waddell, Ian Chau, David Cunningham, David Gonzalez, Alicia Frances Clare Okines, Clare Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley,[...]. Lancet Oncol 2013
505
18

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges,[...]. JAMA Oncol 2018
878
17

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
236
17

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.
Steven B Maron, Lindsay Alpert, Heewon A Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J Nagy, Richard B Lanman, Fabiola Cecchi,[...]. Cancer Discov 2018
74
21

Detection of circulating tumor DNA in early- and late-stage human malignancies.
Chetan Bettegowda, Mark Sausen, Rebecca J Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R Bartlett, Hao Wang, Brandon Luber, Rhoda M Alani,[...]. Sci Transl Med 2014
16

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero,[...]. J Clin Oncol 2016
352
16

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Maria Secrier, Xiaodun Li, Nadeera de Silva, Matthew D Eldridge, Gianmarco Contino, Jan Bornschein, Shona MacRae, Nicola Grehan, Maria O'Donovan, Ahmad Miremadi,[...]. Nat Genet 2016
223
15

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
15

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko,[...]. Lancet Oncol 2017
181
15

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
15

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Angela N Bartley, Mary Kay Washington, Carol Colasacco, Christina B Ventura, Nofisat Ismaila, Al B Benson, Alfredo Carrato, Margaret L Gulley, Dhanpat Jain, Sanjay Kakar,[...]. J Clin Oncol 2017
161
14

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G S Mortimer, Justin I Odegaard, Elizabeth A Harrington, Juyoung Lee, Taehyang Lee,[...]. Cancer Discov 2019
77
18

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Manish A Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S Shames,[...]. JAMA Oncol 2017
156
14

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
13

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
S T Kim, K C Banks, E Pectasides, S Y Kim, K Kim, R B Lanman, A Talasaz, J An, M G Choi, J H Lee,[...]. Ann Oncol 2018
61
21

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
E Van Cutsem, Y-J Bang, W Mansoor, R D Petty, Y Chao, D Cunningham, D R Ferry, N R Smith, P Frewer, J Ratnayake,[...]. Ann Oncol 2017
113
13

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Daniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M Chase, Bryan F Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart,[...]. Cancer Discov 2021
22
59

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
255
13

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang,[...]. J Clin Oncol 2014
397
12

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
231
12

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, Brittanie Millang, Shweta S Chavan, Carly Alterman, Joanne F Chou, Michal F Segal, Marc Z Simmons, Parisa Momtaz,[...]. Lancet Oncol 2020
117
12

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi,[...]. Nat Med 2020
93
12


The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.
Alexander M Frankell, SriGanesh Jammula, Xiaodun Li, Gianmarco Contino, Sarah Killcoyne, Sujath Abbas, Juliane Perner, Lawrence Bower, Ginny Devonshire, Emma Ococks,[...]. Nat Genet 2019
92
11

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
De-Shen Wang, Ze-Xian Liu, Yun-Xin Lu, Hua Bao, Xue Wu, Zhao-Lei Zeng, Zekun Liu, Qi Zhao, Cai-Yun He, Jia-Huan Lu,[...]. Gut 2019
69
15

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Filippo Pietrantonio, Giovanni Fucà, Federica Morano, Annunziata Gloghini, Simona Corso, Giuseppe Aprile, Federica Perrone, Ferdinando De Vita, Elena Tamborini, Gianluca Tomasello,[...]. Clin Cancer Res 2018
62
17

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Eunice L Kwak, Leanne G Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R Borger, Jason T Godfrey, Nicholas A Jessop, Jeffrey W Clark, Lawrence S Blaszkowsky, David P Ryan,[...]. Cancer Discov 2015
125
11

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im,[...]. Lancet Oncol 2017
168
11

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Susan J Dutton, David R Ferry, Jane M Blazeby, Haider Abbas, Asa Dahle-Smith, Wasat Mansoor, Joyce Thompson, Mark Harrison, Anirban Chatterjee, Stephen Falk,[...]. Lancet Oncol 2014
207
11

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Alex Pearson, Elizabeth Smyth, Irina S Babina, Maria Teresa Herrera-Abreu, Noelia Tarazona, Clare Peckitt, Elaine Kilgour, Neil R Smith, Catherine Geh, Claire Rooney,[...]. Cancer Discov 2016
176
11

Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
Katsutoshi Shoda, Daisuke Ichikawa, Yuji Fujita, Kiyoshi Masuda, Hidekazu Hiramoto, Junichi Hamada, Tomohiro Arita, Hirotaka Konishi, Shuhei Komatsu, Atsushi Shiozaki,[...]. Gastric Cancer 2017
85
11

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Christopher Abbosh, Nicolai J Birkbak, Gareth A Wilson, Mariam Jamal-Hanjani, Tudor Constantin, Raheleh Salari, John Le Quesne, David A Moore, Selvaraju Veeriah, Rachel Rosenthal,[...]. Nature 2017
813
10

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
254
10

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong,[...]. Cancer Discov 2019
80
12

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Shumei Kato, Ryosuke Okamura, Joel M Baumgartner, Hitendra Patel, Lawrence Leichman, Kaitlyn Kelly, Jason K Sicklick, Paul T Fanta, Scott M Lippman, Razelle Kurzrock. Clin Cancer Res 2018
57
17

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Pedram Razavi, Bob T Li, David N Brown, Byoungsok Jung, Earl Hubbell, Ronglai Shen, Wassim Abida, Krishna Juluru, Ino De Bruijn, Chenlu Hou,[...]. Nat Med 2019
280
10

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Aparna R Parikh, Ignaty Leshchiner, Liudmila Elagina, Lipika Goyal, Chaya Levovitz, Giulia Siravegna, Dimitri Livitz, Kahn Rhrissorrakrai, Elizabeth E Martin, Emily E Van Seventer,[...]. Nat Med 2019
184
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.